Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries Limited : The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 05:23pm CEST

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) who purchased American Depositary Shares between November 15, 2016 and August 2, 2017. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company's business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company's financial results and business prospects.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
04/20TEVA PHARMACEUTICAL INDUSTRIES : to Present New Data across Multiple Therapeutic..
AQ
04/19PAXMAN PUBL : receives market approval in Mexico and plans Q2 launch with licens..
AQ
04/19P&G Acquires the Consumer Health Business of Merck KGaA, Darmstadt, Germany; ..
AQ
04/19TEVA PHARMACEUTICAL INDUSTRIES : and the Procter & Gamble Company Have Agreed to..
BU
04/17TEVA PHARMACEUTICAL INDUSTRIES : to Present New Data Across Multiple Therapeutic..
BU
04/16HISTADRUT : Teva ignoring potential Ashdod plant buyers
AQ
04/15TEVA PHARMACEUTICAL INDUSTRIES : Israeli unions warn Teva Pharm over plan to clo..
RE
04/10TEVA PHARMACEUTICAL INDUSTRIES LTD ( : Today’s Research Reports on Stocks to Wat..
AC
04/09TEVA PHARMACEUTICAL INDUSTRIES : closing Ashdod plant, laying off 85
AQ
04/09TEVA PHARMACEUTICAL INDUSTRIES : lawsuit over Rimsa buy fizzles out
AQ
More news
News from SeekingAlpha
04/20Teva Continues To Deliver But Analysts Stay Bearish 
04/19Novartis Q1 results weigh on pharma stocks 
04/19U.S. opioid prescriptions down 12% last year, largest drop in 25 years 
04/19Flattening Yield Curve, Trade Tensions, Kinder Morgan (Wall Street Breakfast .. 
04/19WALL STREET BREAKFAST : Rally In Commodities Helps Push Stocks Higher 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0,92x
Capi. / Sales 2019 0,93x
Capitalization 18 119 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target 3,9%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-2.92%18 119
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.75%217 064
NOVARTIS-6.21%213 465
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.21%158 813